(Q48357315)

10 February 2018

title

Trials in palliative treatment--have the goal posts been moved? (English)

1 reference

10 February 2018

2

Ian F Tannock

1 reference

10 February 2018

author name string

Peter Kirkbride

series ordinal

1

1 reference

10 February 2018

publication date

1 March 2008

1 reference

10 February 2018

Lancet Oncology Commission

published in

1 reference

10 February 2018

volume

9

1 reference

10 February 2018

issue

3

1 reference

10 February 2018

page(s)

186-187

1 reference

10 February 2018

Goals of palliative cancer therapy: scope of the problem

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Prophylactic cranial irradiation in extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970041-X

7 January 2021

10.1016/S1470-2045(08)70041-X

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018